Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 7/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330955 | 0.94 | CYP2C8 (0.59) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL143691 | 0.89 | CYP2C8 (0.75) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL12330701 | 0.86 | CYP2C8 (0.62) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL145125 | 0.83 | CYP2C8 (0.75) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL141259 | 0.82 | CYP2C8 (0.72) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL2471972 | 0.80 | CYP2C8 (0.58) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL143480 | 0.78 | CYP2C8 (0.77) | CYP2C8CYP3A4KCNH2NR1I2 | |
| SCHEMBL2471970 | 0.77 | CYP2C8 (0.54) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL18752118 | 0.76 | CYP2C8 (0.56) | CYP2C8CYP3A4KCNH2NR1I2MAPK14 | |
| SCHEMBL120717 | 0.76 | CYP2C8 (0.79) | CYP2C8CYP3A4KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |